Long-term antithrombotic therapy after venous stent placement

Phlebology. 2020 Jul;35(6):402-408. doi: 10.1177/0268355519893819. Epub 2019 Dec 10.

Abstract

Objectives: To examine the prescribing patterns and outcomes of antithrombotic regimens after venous stent placement.

Methods: A total of 87 patients who received inferior vena cava or iliofemoral venous stents were included in the study. A retrospective review was performed to determine the antithrombotic regimens and the subsequent rates of in-stent restenosis, stent thrombosis, and bleeding.

Results: The prescribing patterns of specific antithrombotic regimens were highly variable. In-stent restenosis and stent thrombosis events were observed in 13 of 63 patients (21%) with available follow-up imaging, while major bleeding events were noted in 6 of 87 patients (7%). Triple therapy appeared to reduce the odds of in-stent restenosis/ stent thrombosis when compared to dual antiplatelet therapy (OR = 0.07, P = 0.01).

Conclusions: Substantial variability exists in antithrombotic therapy following venous stenting at our institution. This study demonstrated a reduction of in-stent restenosis/thrombosis events when utilizing triple therapy compared to antiplatelet-only regimens. However, larger prospective trials are needed to more accurately determine the relative risks and benefits of each antithrombotic regimen.

Keywords: Anticoagulation; chronic venous insufficiency; deep vein thrombosis; iliac stenting; venous thromboembolism.

MeSH terms

  • Adult
  • Aged
  • Constriction, Pathologic
  • Female
  • Fibrinolytic Agents / pharmacology*
  • Hemorrhage
  • Humans
  • Iliac Vein
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / pharmacology
  • Retrospective Studies
  • Stents*
  • Tomography, X-Ray Computed
  • Vena Cava, Inferior / physiopathology
  • Venous Thrombosis / drug therapy*
  • Young Adult

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors